Drug Profile
SJ 733
Alternative Names: (+)-SJ 000557733; SJ-557733; SJ-733Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator St. Jude Childrens Research Hospital
- Developer Eisai Co Ltd; Medicines for Malaria Venture; QIMR Berghofer Medical Research Institute; St. Jude Childrens Research Hospital; University of Kentucky
- Class Amides; Antimalarials; Fluorobenzenes; Isoquinolines; Nitriles; Pyridines; Small molecules
- Mechanism of Action PfATP4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Falciparum malaria; Vivax malaria
- No development reported Malaria
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Malaria(In volunteers) in Australia (PO)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Malaria(In volunteers) in USA (PO)
- 15 Apr 2022 University of Kentucky and Eisai completes a phase II trial in Vivax malaria (Combination therapy, Monotherapy, In adults, In the elderly) in Peru (PO) (NCT04709692)